Certolizumab Pegol
| Evidence Level: L5 | Predicted Indications: 3 |
Table of Contents
- Certolizumab Pegol
- Pharmacist Assessment Report
- Certolizumab Pegol: PEGylated anti-TNF-α antibody fragment → hypermobility of coccyx
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- Canada Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Certolizumab Pegol: PEGylated anti-TNF-α antibody fragment → hypermobility of coccyx
One-Sentence Summary
Certolizumab pegol is a PEGylated anti-TNF-α antibody fragment that is marketed in Canada. The TxGNN model predicts it may be effective for hypermobility of coccyx, with a score of 0.9975. No clinical trials and no publications currently support this specific prediction, so it rests on the model score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | hypermobility of coccyx |
| TxGNN Prediction Score | 0.9975 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 2 of 2) |
| Number of DINs | 2 (marketed: 2) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Certolizumab pegol is a polyethylene-glycolylated antigen-binding fragment of a recombinant human monoclonal antibody. It binds to and neutralizes tumour necrosis factor alpha (TNF-α), a key driver of inflammation in immune-mediated joint and spinal disease.
The link to this prediction is weak. Hypermobility of the coccyx is mainly a mechanical or structural condition, and no clear TNF-driven inflammatory mechanism has been identified for it. The retrieved data contain no trials or publications that study this condition with certolizumab pegol or with other TNF inhibitors.
The high model score therefore remains a computational signal only. It would need independent biological or clinical support before it could be treated as a credible repurposing lead.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Canada Market Information
| DIN | Product Name |
|---|---|
| 02465574 | CIMZIA |
| 02331675 | CIMZIA |
Both licences are currently valid single-ingredient products.
Safety Considerations
- Drug Interactions: 100 interactions are recorded in total. The main ones are:
- Major: corticosteroids (hydrocortisone, prednisolone, prednisone, dexamethasone, betamethasone, budesonide, triamcinolone including the ophthalmic form), deferiprone, and the radiopharmaceuticals ibritumomab tiuxetan, iobenguane (I-131) and tositumomab (I-131).
- Moderate: metronidazole, tinidazole, pegvaliase, rosuvastatin and simvastatin.
- Minor: zinc salts (acetate, gluconate, sulfate).
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has a high model score but no supporting trials or literature, and no plausible TNF-related mechanism for a mechanical coccyx condition. Evidence is at the model-prediction-only level (L5).
To proceed, the following is needed:
- A mechanistic rationale showing whether TNF-mediated inflammation contributes to coccyx hypermobility
- Preclinical or clinical data in this condition, such as case series or registered trials
- Package insert warnings and contraindications from Health Canada, for the safety screening
- Detailed mechanism-of-action data from a curated source
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.